Ligne de temps
Maryline Bourgine
Ingénieur(e) de Recherche
07 sept. 2023
publication
Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.
Lire plus18 avr. 2023
publication
Mice Humanized for MHC and hACE2 with High Permissiveness to SARS-CoV-2 Omicron Replication.
Lire plus01 janv. 2023
publication
Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.
Lire plus21 déc. 2022
publication
Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters
Lire plus27 avr. 2022
publication
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Lire plus16 déc. 2021
publication
A virus-derived microRNA targets immune response genes during SARS-CoV-2 infection.
Lire plus07 déc. 2021
publication
Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.
Lire plus29 juil. 2021
18 avr. 2021
16 déc. 2020
publication
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
Lire plus24 juin 2020
publication
Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers.
Lire plus23 juil. 2015
publication
Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes
Lire plus16 déc. 2014
publication
Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?
Lire plus26 nov. 2014
publication
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
Lire plus19 mars 2014
publication
Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection
Lire plus26 déc. 2013
publication